MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
1.130
-0.060
-5.04%
After Hours: 1.120 -0.01 -0.89% 19:54 12/18 EST
OPEN
1.240
PREV CLOSE
1.190
HIGH
1.240
LOW
1.100
VOLUME
108.62K
TURNOVER
--
52 WEEK HIGH
33.25
52 WEEK LOW
1.000
MARKET CAP
5.08M
P/E (TTM)
-0.0209
1D
5D
1M
3M
1Y
5Y
1D
Jaguar Health announces abstract submission for crofelemer preliminary data
TipRanks · 4d ago
Jaguar Health's Napo Pharma's Independent Investigator At SBS-IF Treatment Institution Submits Abstract Describing Preliminary Findings From Clinical Trial Evaluating Oral Liquid Formulation Of Crofelemer In Adult SBS-IF Patients
Benzinga · 4d ago
Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome
Reuters · 4d ago
Weekly Report: what happened at JAGX last week (1208-1212)?
Weekly Report · 4d ago
Jaguar Health Executes Strategic Stock Exchange Agreements
TipRanks · 6d ago
Jaguar Health Issues Pre-Funded Warrants in Exchange for Preferred Stock
Reuters · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/10 21:05
Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation
Reuters · 12/10 19:20
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.